ITF, IntraBio and Orchard are among the companies that have won FDA nods in the past year for Duchenne muscular dystrophy, ...

Zevra has sold its US Food and Drug Administration (FDA) priority review voucher (PRV) for $150m to an undisclosed party. The ...

Investing.com -- Shares of Zevra Therapeutics, Inc. ( Nasdaq: ZVRA) climbed 8% following the announcement that the company has entered into an agreement to sell its Rare Pediatric Disease Priority ...

Rare disease-focused biopharma Zevra Therapeutics has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to an undisclosed buyer for $150 million.

Zevra Therapeutics has inked a deal to sell its Food and Drug Administration priority-review voucher to an undisclosed buyer for gross proceeds of $150 million.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Zevra Therapeutics (ZVRA – Research Report) and Venus ...

For Zevra Therapeutics, last year’s approval of the rare lysosomal storage disorder drug Miplyffa appears to be the gift that ...

Zevra Therapeutics (ZVRA) has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ...

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that it has entered ...

Discover Stoke Therapeutics' innovative RNA-based treatments like zorevunersen for Dravet syndrome, with a promising pipeline ...

Timothy J. Sangiovanni, Senior Vice President of Finance and Corporate Controller at Zevra Therapeutics Inc. (NASDAQ:ZVRA), ...